Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma

Yi,Cunjian; Li,Li; Chen,Keming; Lin,Shengrong; Liu,Xiangqiong

doi:10.3892/ol.2011.481

Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma

Authors:
- Cunjian Yi
- Li Li
- Keming Chen
- Shengrong Lin
- Xiangqiong Liu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, First Affiliated Hospital, Yangtze University, Jingzhou, Hubei 434000, P.R. China
Published online on: November 15, 2011 https://doi.org/10.3892/ol.2011.481
Pages: 369-372

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to investigate the expression of c-Kit and platelet-derived growth factor receptor α (PDGFRα) in epithelial ovarian tumor cells and tumor stroma. The expression of c-Kit and PDGFRα in 71 malignant or benign epithelial ovarian tumor tissues and 20 normal ovarian tissues was evaluated by immunohistochemical staining. The expression of c-Kit and PDGFRα in 71 malignant epithelial ovarian tumors and tumor stroma tissue samples was analyzed. A significant increase (P<0.01) of c-Kit expression was observed in malignant ovarian tumors (50.7%) when compared to normal ovarian tissues (10.0%) or benign ovarian tumors (20.0%). The PDGFRα expression rate in malignant ovarian tumors (63.4%) was also significantly higher (P<0.01) than that in normal ovarian tissues (15.0%) or benign ovarian tumors (25.0%). c-Kit was expressed in only 4.2% of the tumor stroma samples, which was significantly lower than the expression of malignant ovarian tumors (P<0.01), whereas the PDGFRα expression in tumor stroma (87.3%) was significantly higher than that of the malignant ovarian tumors (P<0.01). The expression levels of c-Kit and PDGFRα are higher in the malignant ovarian tumors than in the benign ovarian tumors or normal tissues. In the malignant ovarian tumor stroma, c-Kit expression is low and PDGFRα expression is high, and the differential changes of c-kit and PDGFRα suggest distinct roles in ovarian cancer.

View Figures

View References

1	Marcia LL, Brian PR, Tara LB, et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 156:791–795. 2000. View Article : Google Scholar : PubMed/NCBI
2	Matei D, Chang DD and Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 10:681–690. 2004. View Article : Google Scholar
3	Malaise M, Steinbach D and Corbacioglu S: Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 4:77–82. 2009. View Article : Google Scholar : PubMed/NCBI
4	Chi P, Chen Y, Zhang L, et al: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467:849–853. 2010. View Article : Google Scholar : PubMed/NCBI
5	Schneider BJ, Kalemkerian GP, Ramnath N, et al: Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 11:223–227. 2010. View Article : Google Scholar : PubMed/NCBI
6	Schmandt RE, Broaddus R, Lu KH, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 98:758–764. 2003. View Article : Google Scholar : PubMed/NCBI
7	Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M and Oberg K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53:4550–4554. 1993.PubMed/NCBI
8	Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN and Butzow R: Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer. 91:2048–2055. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yi CJ, Lin SR and Chen KM: Expression and clinical significance of c-kit and PDGFRa in ovarian serous carcinomas. Chinese Journal of Gynecology and Obstetrics. 22:295–296. 2006.
10	Parrott JA, Kim G and Skinner MK: Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 62:1600–1609. 2000. View Article : Google Scholar : PubMed/NCBI
11	Tonary AM, Macdonald EA, Faught W, Senterman MK and Vanderhyden BC: Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 89:242–250. 2000. View Article : Google Scholar : PubMed/NCBI
12	Arber DA, Tamayo R and Weiss LM: Paraffin section detection of the c-Kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 29:498–504. 1998. View Article : Google Scholar : PubMed/NCBI
13	Singer G, Schraml P, Belgard C, et al: KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst. 95:1009–1010. 2003. View Article : Google Scholar : PubMed/NCBI
14	Dabrow MB, Francesco MR, McBrearty FX and Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol. 71:29–37. 1998. View Article : Google Scholar : PubMed/NCBI
15	Apte SM, Bucana CD, Killion JJ, Gershenson DM and Fidler IJ: Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol. 93:78–86. 2004. View Article : Google Scholar : PubMed/NCBI
16	Vigne JL, Halburnt LL and Skinner MK: Characterization of bovine ovarian surface epithelium and stromal cells: identification of secreted proteins. Biol Reprod. 51:1213–1221. 1994. View Article : Google Scholar : PubMed/NCBI
17	Baranowska-Kortylewicz J, Abe M, Pietras K, et al: Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 65:7824–7831. 2005.PubMed/NCBI
18	Yu J, Moon A and Kim HR: Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun. 282:697–700. 2001. View Article : Google Scholar : PubMed/NCBI
19	Bergers G, Song S, Meyer-Morse N, Bergsland E and Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 111:1287–1295. 2003. View Article : Google Scholar : PubMed/NCBI